Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-08-11

FDA Approved: WELLBUTRIN SR — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approved a supplemental application for Wellbutrin SR (bupropion hydrochloride) filed by GlaxoSmithKline LLC, updating the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • WELLBUTRIN SR (BUPROPION HYDROCHLORIDE)

Snippet

SUPPL AP for WELLBUTRIN SR (BUPROPION HYDROCHLORIDE)